Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Nature Communications|October 14, 2025
A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19Rhiannon Edge, Sam Matthews, Bahar Ahani, et al.
Lancet (London, England)|March 8, 2011
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyJavier Cortes, Joyce O'Shaughnessy, David Loesch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019Myron J Levin, Andrew Ustianowski, Steven Thomas, et al.
The Lancet. Respiratory Medicine|June 10, 2022
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trialHugh Montgomery, F D Richard Hobbs, Francisco Padilla, et al.
The Lancet. Microbe|October 2, 2023
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and PolandMaheshi N Ramasamy, Elizabeth J Kelly, Seth Seegobin, et al.
Clinical Drug Investigation|January 16, 2026
Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-studyAndrew Ustianowski, Myron J Levin, Stephane De Wit, et al.
The Lancet. Microbe|June 15, 2024
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging studySue Ann Costa Clemens, Brett Jepson, Qasim E Bhorat, et al.
The New England Journal of Medicine|April 20, 2022
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19Myron J Levin, Andrew Ustianowski, Stéphane De Wit, et al.
Nature Communications|March 10, 2019
Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02Christos Tziotzios, Christos Petridis, Nick Dand, et al.
Pageof 2